AMF

United States: TotalEnergies and Clean Energy Launch the Construction of their First Biogas Unit

Tuesday, November 30, 2021 - 2:00pm

PARIS, Nov. 30, 2021 /PRNewswire/ --Through their joint venture, TotalEnergies and its U.S. partner Clean Energy are launching the construction of their firstbiomethane production unit, in Friona, Texas.

Key Points: 
  • PARIS, Nov. 30, 2021 /PRNewswire/ --Through their joint venture, TotalEnergies and its U.S. partner Clean Energy are launching the construction of their firstbiomethane production unit, in Friona, Texas.
  • The biomethane will be distributed in the United States by Clean Energy through its network of fueling stations, enabling the supply of renewable gas to between 200 and 300trucks per year.
  • Clean Energy Fuels Corp. is the north American largest provider of the cleanest fuel for the transportation market.
  • The terms "TotalEnergies", "TotalEnergies company" or "Company" in this document are used to designate TotalEnergies SE and the consolidated entities that are directly or indirectly controlled by TotalEnergies SE.

AB Science announces dosing of first patient in Phase 2 trial of masitinib’s antiviral activity against the SARS-CoV-2 (COVID-19) virus

Monday, November 29, 2021 - 7:57pm

AB Science SA (Euronext - FR0010557264 - AB) today announced that the first patient has been dosed in the phase 2 trial evaluating the antiviral activity of masitinib in patients who have a confirmed diagnosis of COVID-19.

Key Points: 
  • AB Science SA (Euronext - FR0010557264 - AB) today announced that the first patient has been dosed in the phase 2 trial evaluating the antiviral activity of masitinib in patients who have a confirmed diagnosis of COVID-19.
  • Evidently, there is a continued need for effective antiviral treatments that are insensitive to these variants.
  • It has antiviral activity against the original virus and also against the alpha, beta and delta variants, as is to be expected with an anti-protease drug.
  • AB Science disclaims any obligationor undertaking to update the forward-looking information and statements, subject to the applicable regulations, in particular articles 223-1 et seq.

Société du Grand Paris : final terms serie 17 Issue of EUR 1,250,000,000 1.000 per cent. Notes due 26 November 2051

Thursday, November 25, 2021 - 2:04pm

Socit du Grand Paris : final terms serie 17 Issue of EUR 1,250,000,000 1.000 per cent.

Key Points: 
  • Socit du Grand Paris : final terms serie 17 Issue of EUR 1,250,000,000 1.000 per cent.
  • Notes due 26 November 2051
    Dissemination of a French Regulatory News, transmitted by EQS Group.
  • This document constitutes the Final Terms of the Notes described herein for the purposes of the Prospectus Regulation and must be read in conjunction with such Base Prospectus.
  • The Final Terms and the Base Prospectus will be available on the Issuer's website ( https://www.societedugrandparis.fr/publications-financieres-1870 ) and on the AMF's website ( www.amf-france.org ).

Société du Grand Paris : Final terms - Issue of EUR 1,750,000,000 0.300 per cent. Notes due 25 November 2031

Thursday, November 25, 2021 - 2:04pm

Socit du Grand Paris : Final terms - Issue of EUR 1,750,000,000 0.300 per cent.

Key Points: 
  • Socit du Grand Paris : Final terms - Issue of EUR 1,750,000,000 0.300 per cent.
  • Notes due 25 November 2031
    Dissemination of a French Regulatory News, transmitted by EQS Group.
  • This document constitutes the Final Terms of the Notes described herein for the purposes of the Prospectus Regulation and must be read in conjunction with such Base Prospectus.
  • The Final Terms and the Base Prospectus will be available on the Issuer's website ( https://www.societedugrandparis.fr/publications-financieres-1870 ) and on the AMF's website ( www.amf-france.org ).

Lyxor ETF : Index Switch

Wednesday, November 24, 2021 - 12:07pm

The terms in this letter that begin with uppercase letters are defined in the prospectus of the MULTI UNITS FRANCE - Lyxor New Energy (DR) UCITS ETF.

Key Points: 
  • The terms in this letter that begin with uppercase letters are defined in the prospectus of the MULTI UNITS FRANCE - Lyxor New Energy (DR) UCITS ETF.
  • We hereby inform you that LYXOR INTERNATIONAL ASSET MANAGEMENT, acting in it capacity as the management company (hereafter the "Management Company") of the Lyxor New Energy (DR) UCITS ETF sub-fund (hereafter the "Sub-fund"), has decided to make the following changes:
    In order to accommodate the changing needs of its clients, the Management Company will replace its Benchmark Index, as shown in the table below:
    The MSCI ACWI IMI New Energy ESG Filtered Net Total Return Benchmark Index is an equity index that is calculated and published by the global index provider MSCI.
  • The Benchmark Index seeks to represent the stock-market performance of companies that develop new products and services in the areas of alternative energies, energy efficiency, batteries and smart network technologies.
  • The Sub-fund's name was changed as shown below to more accurately reflect its new Benchmark Index.

Innate Pharma to Participate in the Evercore ISI 4th Annual HealthConX Virtual Conference

Wednesday, November 24, 2021 - 6:00am

Disclaimer on forward-looking information and risk factors:

Key Points: 
  • Disclaimer on forward-looking information and risk factors:
    This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995.
  • The use of certain words, including believe, potential, expect and will and similar expressions, is intended to identify forward-looking statements.
  • Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated.
  • This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

Onxeo Continues to Strengthen its Board of Directors

Tuesday, November 23, 2021 - 6:08pm

Paris (France), Nov. 23, 2021 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North: ONXEO), « Onxeo », a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR) in oncology, today announced the appointment of Bryan Giraudo as independent member of the Board of Directors, replacing Thomas Hofstaetter after three mandates.

Key Points: 
  • Prior to joining LEERINK Partners in 2009, Mr Giraudo was a Managing Director in Merrill Lynchs Global Healthcare Investment Banking Division.
  • Bryan Giraudo, new independent member of the Board of Directors of Onxeo, declared: "I am thrilled to join Onxeos Board of Directors, comprising outstanding experts in different clinical and strategic fields.
  • Shefali Agarwal, Chairwoman of the Board of Directors of Onxeo, commented: On behalf of the entire Board of Directors I would like to thank Thomas Hofstaetter for his important contribution to the development of ONXEO during the past nine years.
  • Judith Greciet, Chief Executive Officer of Onxeo, concluded: "With Bryan joining our Board of Directors today, I am glad that our Company was able to attract such an outstanding group of seasoned professionals.

Biophytis obtains a new 10M€ loan structure with Kreos Capital

Monday, November 22, 2021 - 10:07pm

This new financing structure with Kreos Capital shows the good relationship both Parties are having since 2018".

Key Points: 
  • This new financing structure with Kreos Capital shows the good relationship both Parties are having since 2018".
  • Besides, Kreos Capital will receive Biophytis' share warrants ("bon de souscription d'action" or "BSA") for a total of approximately 1M.
  • As security of its obligations, the Company has pledged certain assets, to the benefit of Kreos Capital.
  • Biophytis will issue for the benefit of Kreos Capital 2 218 293 share warrants (BSAs) giving the right to subscribe to new Biophytis ordinary shares, on the basis of one share for one BSA.

Pharnext appoints Dr. Burkhard Blank as new Chief Medical Officer and Head of Research & Development

Monday, November 22, 2021 - 7:21pm

Dr. Burkhard Blank is an experienced leader in global drug development, medical and regulatory affairs, and pharmacovigilance with more than 25 years of industry experience.

Key Points: 
  • Dr. Burkhard Blank is an experienced leader in global drug development, medical and regulatory affairs, and pharmacovigilance with more than 25 years of industry experience.
  • He joins Pharnext from Acorda Therapeutics where he held the position of CMO and Head of Research & Development for the past six years.
  • Prior to this, Dr Blank served as CMO for several biopharmaceutical companies, including Boehringer Ingelheim, Herantis Pharma, and Mersana Therapeutics.
  • Dr. David Horn Solomon, Chief Executive Officer of Pharnext, commented: "I am delighted to welcome Burkhard to the team and look forward to working with him.

Waga Energy: Waga Energy confirms the success of its initial public offering with the full exercise of the over-allotment option

Monday, November 22, 2021 - 7:19pm

The registration document and its supplement contain a detailed description of Waga Energy.

Key Points: 
  • The registration document and its supplement contain a detailed description of Waga Energy.
  • Waga Energy would like to draw the public's attention to Chapter 3: "Risk Factors" in the registration document approved by the AMF.
  • An innovative company, Waga Energy has developed a purification technology that is unique in the world, combining membrane filtration and cryogenic distillation.
  • As of 31 July 2021, Waga Energy operates ten WAGABOX(R) units in France, with a maximum installed capacity of 225 GWh/year.